Drug Trial Radar · NCT07703683
Myokines as Potential Biomarkers and Drivers of Sarcopenia in Metabolic and Endocrine Diseases
Last checked: Nov 20, 2026Latest source record: Jul 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Feb 19, 2026
Primary completion
Dec 31, 2056
Study completion Dec 31, 2056
Sponsor
- Lead sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de LouvainAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 14, 2026
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Prospective, observational, single-center, study evaluating the prevalence of sarcopenia / sarcopenic obesity in individuals with metabolic and / or endocrine diseases, as well as the potential role of myokines as biomarkers or drivers of sarcopenia / sarcopenic obesity in this population. .
Conditions
- Diabetes
- Obesity & Overweight
- Cushing Syndrome
- Metabolic Diseases
- Endocrine Diseases
- Sarcopenia
- Sarcopenic Obesity
Interventions
GLP-1 Receptor AgonistsDrug
Participants receive GLP-1 RA or GLP-1/GIP dual agonists as part of their standard care for overweight or obesity
Primary outcomes
What the sponsor says the trial is designed to measure.
- Prevalence of sarcopenia / sarcopenic obesityTime frame: From February 2026 to december 2056
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cliniques Universitaires Saint-Luc
Woluwe-Saint-Pierre - Sint-Pieters-Woluwe, Belgium · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.